Skip to content
Adam Torkildson – Lifestyle
Author:
Greywolf Therapeutics
Greywolf Therapeutics ERAP1 inhibitor dosed in axSpA trial
September 8, 2026
Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types
June 2, 2026
Greywolf Therapeutics appoints Edwin Moses as Chair
April 16, 2026